02367 GIANT BIOGENE
- 52.950
- +0.950+1.83%
GIANT BIOGENE News
Giant Biotech (2367.HK) tracking review: Online channels continue to boost makeup device collaboration to help growth
The volume of core single products helps increase performance. The company achieved operating revenue of 3,524 billion yuan in 2023, +49.05% year over year; among these, revenue from effective skincare products achieved a high increase of +69.52% over the same period last year to 2,647 billion yuan.
The market is picking up, and listed companies are pouring in medical and aesthetic institutions. Who will win the next “C-rank material”?
Catalyzed by various factors, the medical and aesthetic market recovered to a certain extent in the first quarter, while the performance of listed companies, whether midstream medical and aesthetic institutions or upstream producers, has steadily improved since this year.
Giant Biogene's Profit Up 47% in 2023
Giant Biogene Holding (HKG:2367) recorded a 47% rise in attributable profit for the year 2023 to 1.45 billion yuan, from 1 billion yuan in 2022, according to the company's annual report posted on the
巨子生物：二零二三年年報
Giant Biotech (02367.HK): Kefumei's large single product volume continues to focus on medical and aesthetic products approved for catalysis
Incident: The company released its 2023 annual report: 2023 revenue of 3,524 billion yuan (+49.0% YoY), net profit to mother of 1,452 billion yuan (+44.9% YoY), adjusted net profit of 1,469 million yuan
Giant Life (02367.HK): Good Wind takes the lead in recombinant collagen to Qingyun
Collagen: a new favorite in dressings, skincare, medicine and beauty, a blue ocean track with high barriers and high profitability. Question 1. Why are you optimistic about the collagen industry? ——After hyaluronic acid, the gold outlet 1) “Manjin Oil” ingredient has rich application scenarios and is suitable
Giant Biotech (2367.HK) Investment Value Analysis Report: The recombinant collagen market is expected to grow rapidly, and the company's star products achieve word-of-mouth and sales growth
The recombinant collagen market is expected to maintain rapid growth in the future. Compared with animal-derived collagen, recombinant collagen has higher biological activity and biocompatibility, lower immunogenicity, lower risk of hidden hazards of missed pathogens, greater water solubility, and less fine
A quick overview of the Hong Kong market | The three major indices closed up slightly, and the Hang Seng Index stopped falling for 4 consecutive years
Semiconductor stocks strengthened, with Shanghai Fudan up more than 8%; heavy infrastructure stocks rose, with China Metallurgical, China Railway, and China Communications Construction up about 3%.
Hong Kong Stock Afternoon Review | Hang Seng Index and Technology Index fell slightly; chip stocks rose more than 5% in Fudan, Shanghai
Heavy infrastructure stocks generally rose; China Zhongzhi and China Railway rose about 3%; gaming stocks continued to decline, and Galaxy Entertainment fell more than 5%.
Changes in Hong Kong stocks | Being well received by institutions, Giant Biotech once rose more than 5% and then hit a new high
Gelonghui, April 17 | Giant Biotech (2367.HK), a leader in the recombinant collagen industry, rose more than 5% during the intraday period, reaching a new high of HK$46.1, with a market value of HK$45 billion. According to the news, the company recently announced net profit of 1,452 billion yuan to the mother in '23, an increase of 44.88% over the previous year. Haitong Securities maintains Giant Biotech's “superior to the market” rating and is optimistic about the development prospects of the collagen industry chain. I am optimistic that the company will continue to expand its growth space in multiple categories, multiple series, and multiple scenarios, and stabilize its leading position. Guosheng Securities, on the other hand, maintained the company's “buy” rating, indicating that it is gradually steadily promoting the collaborative development of cosmetics.
Changes in Hong Kong stocks | Giant Biotech (02367) rose more than 5%, technological progress drives industry growth, institutions believe there is plenty of room for growth in the recombinant collagen industry
Giant Biotech (02367) rose by more than 5%. As of press time, it rose 5.51% to HK$45.95, with a turnover of HK$76.93 million.
Giusi Biotech (02367.HK) Annual Report Review Report: The company's performance achieved impressive growth and steadily promoted the collaborative development of cosmetic equipment
The results in 2023 were impressive, with revenue/net profit increasing by 49%/45%, respectively. In 2023, the company achieved operating income of 3,524 billion yuan (yoy +49.0%) and realized net profit of 1,452 billion yuan to mother
Giant Biotech (2367.HK) 2023 Report Review: Expanding Multiple Categories and Multiple Scenes to Accelerate Online Penetration
Giant Biotech released its 2023 annual report: achieved revenue of 3,524 billion yuan in 2023, up 49.05% year on year; net profit to mother was 1,452 billion yuan, up 44.88% year on year, and adjusted net profit of 14.69 billion yuan
Express News | General Administration of Market Regulation: Maintain a high-pressure crackdown on illegal acts of medical and aesthetic advertising and strictly regulate the publication of medical and aesthetic advertisements
Trends in Hong Kong biotechnology stocks diverged. Cansino Biotech rose more than 10%, Yiming Anke rose more than 9%, Laikai Pharmaceuticals and Yasheng Pharmaceuticals all rose more than 6%, and Giants Biotech fell more than 2%.
Trends in Hong Kong biotechnology stocks diverged. Cansino Biotech rose more than 10%, Yiming Anke rose more than 9%, Laikai Pharmaceuticals and Yasheng Pharmaceuticals all rose more than 6%, and Giants Biotech fell more than 2%.
The sales expense ratio is as high as 33% How can Giazi Biotech get rid of dependence on large single products
In March, Juzi Biotech (02367.HK), the “first recombinant collagen stock”, released financial reports.
Giusi Biotech (2367.HK) 2023 Annual Report Review: Performance Exceeds Expectations, Skin Revitalization Products are progressing smoothly
The incident described Juzi Biotech's revenue in 2023 was 3,524 billion yuan, up 49% year on year, and net profit to mother was 1.45 billion yuan, up 45% year on year, achieving adjusted net profit of 1.47 billion yuan, up 39% year on year
Giant Biotech (02367.HK): The core single product, a high-speed growth injection product, is about to be launched
Description of the incident On March 25, Giant Biotech released the 2023 results announcement. In 2023, it achieved operating income of 3,524 billion yuan, an increase of 49.0% over the previous year; achieved net profit of 1,452 billion yuan, an increase of 4
Express News | Zhang Kun of E-Fangda Fund made a major change in position! Zhang Kun buys a large number of women's consumer circuits
Giant Biotech (02367.HK): Big Single Product Methodology Begins to Show Optimism for Collaborative Development of Makeup Devices
Matters: In '23, the company achieved revenue of 3,524 billion yuan, an increase of 49.0% over the previous year; achieved net profit of 1,452 billion yuan, an increase of 44.9% over the previous year, and achieved adjusted net profit of 1,469 billion yuan, an increase of 3
Analysis
Price Target
No Data
